Success Stories: Transforming Neurodegeneration Research: EB1A Approval for Leading Scientist in neurodegeneration Studies

Client’s Testimonial:

“It was a pleasure working with Chen on my EB-1A case, and I am incredibly grateful for their dedicated support throughout my EB-1A petition. Their team was professional, thorough, and highly responsive from the first day. They ensured that my petition accurately reflected my work and achievements, which made a significant difference. Thanks to their hard work and attention to detail, my EB-1A petition was approved without any RFE. I highly recommend their services to anyone seeking assistance with their immigration needs.”

On June 21^st, 2025, we received another EB1A (Alien of Extraordinary Ability) approval for a Research Associate in the Field of Neurodegeneration (Approval Notice).

General Field: Neurodegeneration

Position at the Time of Case Filing: Research Associate

Country of Origin: India

State of Residence at the Time of Filing: Maryland

Approval Notice Date: June 21^st, 2025

Processing Time: 16 days (Premium Processing Requested)

Case Summary:

In the search for answers to some of the most devastating neurological diseases, a dedicated research associate from India is helping redefine what’s possible. With a focus on neurodegenerative disorders, this accomplished scientist has recently secured EB1A (Alien of Extraordinary Ability) approval—a testament to her groundbreaking research and sustained influence in her field.

Her work centers on uncovering cellular dysfunction in neurodegeneration and factors contributing to neurodegenerative disease progression. Her research portfolio includes 10 peer-reviewed journal articles and a book chapter, with work published in some of the field’s most prestigious venues, such as Science Translational Medicine, etc. Her work has been cited over 200 times by peers across 29 countries, a clear indication of its international impact.

Notably, her extensive studies have been implemented by top researchers worldwide. Scholars from institutions such as Stanford, Oxford, the University of Calgary, and the Weizmann Institute have referenced her findings to guide their own investigations into neurodegenerative disorders and neuroprotective therapies.

Beyond authorship, her reputation as a thought leader is evident in her peer review contributions—she has reviewed for more than 36 scholarly journals and serves on the editorial board of a prestigious journal. Her research has also been supported by major funding agencies, including the U.S. Department of Defense’s Multiple Sclerosis Research Program and the Indian Council of Medical Research.

One senior professor summarized her contribution best:

“[Client’s] projects have progressed our understanding of the mechanisms behind ALS and contributed valuable data for the development of ALS therapies. Her expertise is invaluable to advancing our understanding of ALS in the U.S. and worldwide.”

With this EB1A approval, she is now poised to continue her research in the United States, working to decode the molecular underpinnings of neurodegenerative diseases and translate them into real-world treatments. Her focus includes studying key pathways of immune responses in neuroinflammatory and neurodegenerative conditions. At NAILG, we are honored to have supported her journey through the EB1A process. Her story represents not only an extraordinary scientific achievement but also the promise of a better future for patients living with neurodegenerative diseases.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.